Physician profile
Peggy Chern
NPI 1982716783
$5,650.04
in general payments reported to CMS, 2019-2025
27 companies · $940 in 2025
The $940 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $171 · 2021: $770 · 2022: $886 · 2023: $1,098 · 2024: $1,081 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,023 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,022.68 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,706.44 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $513.74 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $432.30 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $386.81 | 2019-2024 | |
| Leo Pharma INC. | $320.91 | 2019-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $296.68 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $227.19 | 2019-2025 | Odomzo, Blu-U |
| Allergan, INC. | $220.33 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $174.27 | 2021 | |
| Genzyme Corporation | $163.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $150.19 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $146.14 | 2023-2025 | Zoryve |
| Biofrontera INC. | $130.47 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Revance Therapeutics, INC. | $119.91 | 2025 | Daxi |
| Lilly USA, LLC | $118.90 | 2019-2024 | Taltz, Olumiant, Ebglyss |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $97.75 | 2019 | |
| Ucb, INC. | $96.34 | 2019-2025 | Bimzelx |
| Pfizer INC. | $70.67 | 2021-2023 | |
| Botanix Sb INC | $58.53 | 2025 | Sofdra |
| Incyte Corporation | $54.51 | 2025 | Opzelura |
| Dusa Pharmaceuticals, INC. | $50.57 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.82 | 2021-2024 | Cabtreo |
| Convatec INC. | $21.50 | 2024 | |
| Kerecis Limited | $16.02 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Lnhc, INC | $15.64 | 2025 | Zelsuvmi |
| Amgen INC. | $15.60 | 2020 | |
| Journey Medical Corporation | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peggy Chern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.